{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
homatropine methylbromide
to a specific field?
There is one exact (name or code) match for homatropine methylbromide
Status:
US Approved Rx
(1983)
Source:
ANDA088017
(1983)
Source URL:
First approved in 1943
Source:
HYCODAN by GENUS
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Homatropine methylbromide or Methylhomatropine bromide is a quaternary ammonium salt of methylhomatropine. It is a peripherally acting anticholinergic medication that inhibits muscarinic acetylcholine receptors and thus the parasympathetic nervous system. Certain preparations of drugs such as hydrocodone are mixed with a small, sub-therapeutic amount of homatropine methylbromide to discourage intentional overdose.
Status:
US Approved Rx
(1983)
Source:
ANDA088017
(1983)
Source URL:
First approved in 1943
Source:
HYCODAN by GENUS
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Homatropine methylbromide or Methylhomatropine bromide is a quaternary ammonium salt of methylhomatropine. It is a peripherally acting anticholinergic medication that inhibits muscarinic acetylcholine receptors and thus the parasympathetic nervous system. Certain preparations of drugs such as hydrocodone are mixed with a small, sub-therapeutic amount of homatropine methylbromide to discourage intentional overdose.
Status:
US Approved Rx
(2000)
Source:
NDA020989
(2000)
Source URL:
First approved in 2000
Source:
NDA020989
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Cevimeline is a cholinergic agonist, which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome. Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping. Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. Drugs with para-sympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects. Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.
Status:
US Approved Rx
(1983)
Source:
ANDA088017
(1983)
Source URL:
First approved in 1943
Source:
HYCODAN by GENUS
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Homatropine methylbromide or Methylhomatropine bromide is a quaternary ammonium salt of methylhomatropine. It is a peripherally acting anticholinergic medication that inhibits muscarinic acetylcholine receptors and thus the parasympathetic nervous system. Certain preparations of drugs such as hydrocodone are mixed with a small, sub-therapeutic amount of homatropine methylbromide to discourage intentional overdose.
Status:
US Approved Rx
(2024)
Source:
ANDA215618
(2024)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.
Status:
Investigational
Source:
JAN:HYOSCYAMINE METHYLBROMIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Hyoscyamine methylbromide, a muscarinic acetylcholine receptor antagonist, was studied as an antispasmodic.
Status:
US Previously Marketed
First approved in 1960
Class (Stereo):
CHEMICAL (ACHIRAL)
Methyl thihexinolium (or thihexinol methylbromide) can inhibit the intestinal hypermotility. Information about the current use of this compound is not available.
Status:
US Previously Marketed
Source:
PIPTAL-PHB PIPENZOLATE BROMIDE by LAKESIDE
(1961)
Source URL:
First approved in 1955
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Pipenzolate bromide (JB-323), an anticholinergic agent, which binds to muscarinic acetylcholine receptors as an antagonist. Pipenzolate bromide was studied as an antispasmodic agent, and to treat peptic ulcer.
